ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,681Medicare Part D Prescriptions Filled, Including Refills

Rank: 187 out of 783

$691K Total Retail Price of All Prescriptions

Rank: 141 out of 783

559 Patients Receiving at Least One Drug in Part D
67%Patients 65 Years and Older
42% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Indiana
Lower avg

Schedule Two
Controlled Substances

3% of this provider’s 559 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

14% of this provider’s 559 patients filled at least one prescription for a schedule three drug, compared to an average of 16%.

Risky Drugs to Seniors

4% of this provider’s 6,916 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$71 was the average price of a prescription from this provider, compared to $61 among peers.

Prescriptions per Patient

17 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Indiana
OMEPRAZOLE 1,267 867 1 6
NEXIUM 332 132 2 28
HYDROCODONE-ACETAMINOPHEN 285 185 S3 3 2
LEVOTHYROXINE SODIUM 274 228 4 1
DICYCLOMINE HCL 264 94 5 200
MELOXICAM 194 133 6 37
FUROSEMIDE 186 157 7 7
LISINOPRIL 156 117 8 4
ZOLPIDEM TARTRATE 150 108 9 23
METOCLOPRAMIDE HCL 149 66 10 121
SIMVASTATIN 143 120 11 3
METOPROLOL SUCCINATE 142 130 12 13
METFORMIN HCL 131 90 13 8
DEXILANT 125 38 14 225
POLYETHYLENE GLYCOL 3350 121 85 15 43
POTASSIUM CHLORIDE 120 109 16 16
GABAPENTIN 119 105 17 15
PRAVASTATIN SODIUM 119 91 17 14
TRAMADOL HCL 114 107 19 20
ATORVASTATIN CALCIUM 112 102 20 11
PANTOPRAZOLE SODIUM 112 51 20 30
SUCRALFATE 110 21 22 190
WARFARIN SODIUM 105 83 23 10
CITALOPRAM HBR 98 80 24 19
ASACOL 96 45 25 327
AMLODIPINE BESYLATE 86 86 26 5
ATENOLOL 85 75 27 17
FLUOXETINE HCL 82 68 28 45
KLOR-CON M20 80 31 29 48
TAMSULOSIN HCL 80 74 29 26
HYDROCHLOROTHIAZIDE 80 80 29 12
CILOSTAZOL 75 75 32 232
METOPROLOL TARTRATE 74 71 33 9
CRESTOR 72 45 34 27
CLOPIDOGREL 72 44 34 29
CARBIDOPA-LEVODOPA 71 70 36 88
ALENDRONATE SODIUM 71 59 36 25
ESCITALOPRAM OXALATE 71 66 36 54
TRAZODONE HCL 66 48 39 39
NAMENDA 64 54 40 32
CYMBALTA 64 54 40 35
PROMETHAZINE HCL 61 18 R 42 97
CARAFATE 60 40 43 358
PLAVIX 60 46 43 51
LANSOPRAZOLE 59 18 45 177
BUSPIRONE HCL 59 45 45 124
AMITRIPTYLINE HCL 55 55 R 47 77
MECLIZINE HCL 55 53 47 146
ISOSORBIDE MONONITRATE ER 52 40 49 40
GLYCOPYRROLATE 52 19 49 440
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Feb. 22, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.